All In Biotech

NDA 016763 · Rising

Sulfamylon

Mafenide Acetate · Topical

Priority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Dec 13, 2002 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1969

Jan 24, 1969

Approved uses

1

Original approval plus efficacy supplements

Registered trials

4

1 Phase 3, 0 recruiting

FAERS reports

31

25 serious, 4 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 3, 2023.

INDICATIONS AND USAGE SULFAMYLON Cream is a topical agent indicated for adjunctive therapy of patients with second- and third-degree burns.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 24, 1969 Original approval · Type 2 - New Active Ingredient · priority review
1 products under this application
  • SULFAMYLON · MAFENIDE ACETATE EQ 85MG BASE/GM · CREAM, TOPICAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Mafenide" as an intervention, any sponsor and status, largest first.

All 4 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective4
  • pyrexia4
  • sepsis4
  • wound infection3
  • agitation2
  • anxiety2
  • clostridium difficile colitis2
  • dry skin2
  • erythema2
  • fatigue2
  • gait disturbance2
  • hypotension2

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041
20051
20061
20081
20122
20141
20154
20164
20186
20192
20201
20212
20222
20231
20241
20251

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Sulfamylon (Mafenide Acetate)

2024 spending

$51K

Beneficiaries

297

447 claims

Per beneficiary

$172

$1.25 per unit

View as table
YearSpending
2020$0
2021$15,730
2022$50,898
2023$52,452
2024$51,044

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 9 on PubMed

Sponsor: Rising

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.